Moreover, B-Raf proto-oncogene (BRAF) mutation (BRAFV600) in melanoma favors collagen-rich environment generated by CAFs, while dual targeting DDR1 and DDR2 contributes to the efficacy of imatinib in vivo [561]. This evidence concerns the gene BRAF and melanoma.